Read by QxMD icon Read

Stage 4 colorectal cancer

Xinyu Wu, Olivia Snir, Douglas Rottmann, Serena Wong, Natalia Buza, Pei Hui
Mismatch-repair deficiency testing plays a critical role in the identification of proband in Lynch Syndrome families and triaging patients with high stage or recurrent solid malignancies for check point inhibitor (Pembrolizumab) immunotherapy. We compared microsatellite shift patterns of microsatellite instability PCR analysis at 5 NCI recommended loci between microsatellite instability high endometrial carcinoma (n = 50) and microsatellite instability high colorectal cancer (n = 19). The endometrial cancer cohort included 45 endometrioid, 1 serous, and 4 clear cell carcinomas...
November 15, 2018: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
J Vodička, Š Vejvodová, M Pešta, P Mukenšnabl, V Špidlen, V Kulda, K Houfková, O Topolčan
INTRODUCTION: The aim of this article is to compare the sensitivity of detecting micrometastases in hilar and mediastinal lymph nodes in case of primary (non-small cell) and secondary (metastases of colorectal carcinoma) pulmonary tumours using standard histopathological examination with haematoxylin-eosin staining, immunohistochemistry examination with Anti-Cytokeratin 19 antibody and examination based on the One-Step Nucleic Acid Amplification method. METHOD: During radical surgical treatment of primary non-small cell lung carcinoma and pulmonary metastases of colorectal carcinoma, hilar and mediastinal lymph nodes of 100 patients enrolled in the study in the period from 2015 to 2017 were extracted based on a standard classification...
2018: Rozhledy V Chirurgii: Měsíčník Československé Chirurgické Společnosti
Seok Won Jin, Jongwook Lee, Sohye Lee
INTRODUCTION: For Korean Americans (KAs), colorectal cancer (CRC) screening rates remain lower than the national target. This study aimed to examine factors predicting decisional stage of CRC screening adoption among older KAs using the precaution adoption process model. METHOD: Convenience sampling was employed to recruit KAs aged 50 to 75 years from the Atlanta metropolitan area in the United States. A total of 433 KAs completed a cross-sectional survey that collects information on sociodemographics, CRC screening history, a physician's recommendation, knowledge, self-efficacy, and decisional balance pertaining CRC screening, and precaution adoption process model stage...
November 15, 2018: Journal of Transcultural Nursing: Official Journal of the Transcultural Nursing Society
Jing Qian, Kaja Tikk, Korbinian Weigl, Yesilda Balavarca, Hermann Brenner
BACKGROUND: Despite evidence that inflammation and metabolism play a crucial role in colorectal carcinogenesis, there have been few studies on the association of inflammatory and metabolic protein biomarkers in various stages of colorectal carcinogenesis. METHODS: Ninety-two inflammatory and metabolic biomarkers were measured in plasma samples of participants of screening colonoscopy. Markers identified to be significantly associated with the presence of advanced colorectal neoplasia (ACN) in a discovery set (n = 204) were validated in an independent replication set (n = 422)...
November 14, 2018: British Journal of Cancer
X R Hu, C Xu, Y Kang, T Wang, Y Zhang, X H Yang
Objective: To investigate the expression of mismatch repair (MMR) proteins (MLH1, MSH2, MSH6 and PMS2) in colorectal cancers and to explore the relationship between MMR expression and clinicopathologic features. Methods: Six hundred and fifty-eight colon cancers were collected from January 2016 to January 2017 at Shengjing Hospital of China Medical University. Of the 658 patients there were 409 male and 249 female. The patients were 20 to 92 years old, with average age of (63±5) years old. Expression of MLH1, MSH2, MSH6 and PMS2 protein was detected by immunohistochemical method...
November 8, 2018: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
In Sub Jung, Cheol Min Shin, Sung Jae Park, Young Soo Park, Hyuk Yoon, Hyun Jin Jo, Nayoung Kim, Dong Ho Lee
Background/Aims: To examine whether visceral adiposity serves as a risk factor for colorectal cancer (CRC) and colorectal adenomas. Methods: Two hundred healthy subjects, 200 patients with colorectal adenoma, and 151 patients with CRC (46 with early-stage and 105 with advanced-stage cancers) were enrolled at a tertiary referral hospital. All subjects underwent colonoscopy, and had laboratory data, and computed tomography (CT) scan available for abdominal fat measurement...
November 12, 2018: Intestinal Research
Yousef S Khader, Ghazi F Sharkas, Kamal H Arkoub, Mahmoud A Alfaqih, Omar F Nimri, Albaraa M Khader
Objectives: This study aimed to determine the overall incidence, trend, and epidemiology of cancer among Jordanians from 2000 to 2013 using data extracted from Jordan's Cancer Registry (JCR). Methods: All cancer cases among Jordanians registered between 2000 and 2013 were analyzed using CanReg software and SPSS. The overall crude incidence rates (CIRs) and the age standardized rates (ASRs) of cancer per 100,000 were calculated. Results: A total of 58788 cancer cases were registered during the period 2000-2013...
2018: Journal of Cancer Epidemiology
Yasmin A Zerhouni, Quoc-Dien Trinh, Stuart Lipsitz, Joel Goldberg, Jennifer Irani, Ronald Bleday, Adil H Haider, Nelya Melnitchouk
BACKGROUND: Colorectal cancer screening decreases incidence and improves survival. Minorities and low-income patients have lower screening rates. The Affordable Care Act increased insurance coverage for low-income Americans by funding Medicaid expansion. Not all states expanded Medicaid. The effect of Medicaid expansion on colorectal cancer screening is unknown. OBJECTIVE: This study aimed to evaluate if Medicaid expansion improved colorectal cancer screening for minorities and low-income patients...
November 7, 2018: Diseases of the Colon and Rectum
Matthew C Cheung, Jill Tinmouth, Peter C Austin, Hadas D Fischer, Kinwah Fung, Simron Singh
BACKGROUND: Cancer screening aims to detect malignant disease early in its natural history when interventions might improve patient outcomes. Such benefits are unclear when screening occurs for patients with an existing high risk of death. Our aim was to study the extent of routine cancer screening for a new primary cancer in patients with existing metastatic cancer. METHODS: We used administrative databases from Ontario to identify a retrospective cohort of adults of eligible screening age (≥ 50 yr) who had a diagnosis of stage IV (metastatic) colorectal, lung, breast or prostate cancer between 2007 and 2012...
October 2018: CMAJ Open
Anne Trinh, Claudia Lädrach, Heather E Dawson, Sanne Ten Hoorn, Peter J K Kuppen, Marlies S Reimers, Miriam Koopman, Cornelis J A Punt, Alessandro Lugli, Louis Vermeulen, Inti Zlobec
BACKGROUND: Tumour budding is an important prognostic factor in colorectal cancer (CRC). Molecular profiling of tumour buds suggests (partial) epithelial-mesenchymal transition and cancer stem-cell phenotype, similarly described in the "mesenchymal" Consensus Molecular Subtype 4 (CMS4), which identifies a particularly poor prognostic subgroup. Here, we determine the association of tumour budding with CMS classification, prognosis, and response to therapy. METHODS: AMC-AJCCII-90 cohort (n = 76, stage II) was evaluated for peritumoural budding on H&E slides...
November 2, 2018: British Journal of Cancer
Kazuhiko Yoshimatsu, Masaya Satake, Megumi Sano, Asaka Kodera, Rie Imaizumi, Yoshitomo Ito, Taro Koike, Hajime Yokomizo, Yuki Yano, Sachiyo Okayama, Yasufumi Yamada, Shinichi Asaka, Takebumi Usui, Kentaro Yamaguchi, Shunichi Shiozawa, Takeshi Shimakawa, Takao Katsube, Yoshihiko Naritaka
INTRODUCTION: There are few reports on the outcome of relapsed cases after curative resection for colorectal cancer(CRC) with adjuvant oxaliplatin-based chemotherapy. Thus, we analyzed such cases. PATIENTS AND METHOD: In total, 48 patients with CRC who received oxaliplatin-based postoperative adjuvant chemotherapy from 2012 were analyzed. The clinical course was examined in 9 cases ofrecurrence. RESULTS: Stages II, III a, and III b(1, 3, and 5 cases, respectively)were judged as recurrence in 9 cases...
October 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Khadija Slik, Sami Blom, Riku Turkki, Katja Välimäki, Samu Kurki, Harri Mustonen, Caj Haglund, Olli Carpén, Olli Kallioniemi, Eija Korkeila, Jari Sundström, Teijo Pellinen
Tumour budding predicts survival of stage II colorectal cancer (CRC) and has been suggested to be associated with epithelial-to-mesenchymal transition (EMT). However, the underlying molecular changes of tumour budding remain poorly understood. Here, we performed multiplex immunohistochemistry (mIHC) to phenotypically profile tumours using known EMT-associated markers: E-cadherin (adherence junctions), integrin β4 (ITGB4; basement membrane), ZO-1 (tight junctions), and pan-cytokeratin. A subpopulation of patients showed high ITGB4 expression in tumour buds, and this coincided with a switch of ITGB4 localisation from basal membrane of intact epithelium to the cytoplasm of budding cells...
October 25, 2018: Journal of Pathology. Clinical Research
Nelya Melnitchouk, Galyna Shabat, Pamela Lu, Heather Lyu, Rebecca Scully, Krystle Leung, Molly Jarman, Andrey Lukashenko, Olena O Kolesnik, Joel Goldberg, Jennifer S Davids, Ronald Bleday
PURPOSE: The incidence of colorectal cancer (CRC) is increasing worldwide, and the greatest increase is in low- to middle-income countries, such as Ukraine. Better knowledge of epidemiology of CRC in Ukraine is needed to understand how best to decrease the burden of disease. METHODS: The National Cancer Registry of Ukraine (NCRU) was queried for CRC incidence, mortality, stage, and treatment in Ukraine and assessed for regional variation from 1999 to 2015. Joinpoint analysis was used to analyze the trends...
October 2018: Journal of Global Oncology
Elena De Mattia, Eva Dreussi, Marcella Montico, Sara Gagno, Chiara Zanusso, Luca Quartuccio, Salvatore De Vita, Michela Guardascione, Angela Buonadonna, Mario D'Andrea, Nicoletta Pella, Adolfo Favaretto, Enrico Mini, Stefania Nobili, Loredana Romanato, Erika Cecchin, Giuseppe Toffoli
There are clinical challenges related to adjuvant treatment in colorectal cancer (CRC) and novel molecular markers are needed for better risk stratification of patients. Our aim was to integrate our previously reported clinical-genetic prognostic score with new immunogenetic markers of 5-year disease-free survival (DFS) to evaluate the recurrence risk stratification before fluoropyrimidine (FL)-based adjuvant therapy. The study population included a total of 270 stage II-III CRC patients treated with adjuvant FL with (FL + OXA, n = 119) or without oxaliplatin (FL, n = 151)...
2018: Frontiers in Pharmacology
Ronald E Myers, Brian Stello, Constantine Daskalakis, Randa Sifri, Evelyn T Gonzalez, Melissa DiCarlo, Melanie B Johnson, Sarah E Hegarty, Kyle Shaak, Alicia Rivera, Lucas Gordils-Molina, Anett Petrich, Beth Careyva, Rosa de-Ortiz, Liselly Diaz
BACKGROUND: Effective strategies are needed to raise colorectal cancer (CRC) screening rates among Hispanics Methods: We surveyed and randomized 400 Hispanic primary care patients either to a Decision Support and Navigation Intervention (DSNI) Group (n=197) or a Standard Intervention (SI) Group (n=203). Both groups received a CRC screening kit (bilingual informational booklet, fecal immunochemical stool blood test (SBT), and colonoscopy screening instructions). The DSNI Group received a telephone contact from a patient navigator...
October 17, 2018: Cancer Epidemiology, Biomarkers & Prevention
Zhong Ye, Chun Wang, Limin Guo, Juan P Palazzo, Zhixing Han, Yinzhi Lai, Jing Jiang, James A Posey, Atrayee Basu Mallick, Bingshan Li, Li Jiang, Hushan Yang
Background: Use of chemotherapy in stage II colorectal cancer (CRC) is controversial because it improves survival only in some patients. We aimed to develop a statistical model using routine and readily available blood tests to predict the prognosis of patients with stage II CRC and to identify which patients are likely to benefit from chemotherapy. Methods: We divided 422 patients with stage II CRC into a training and a testing set. The association of routine laboratory variables and disease-free survival (DFS) was analyzed...
October 2018: Journal of the National Comprehensive Cancer Network: JNCCN
Akimasa Fukuta, Takashi Saito, Shunsuke Murata, Daisuke Makiura, Junichiro Inoue, Maho Okumura, Yoshitada Sakai, Rei Ono
OBJECTIVES: The aim of the present study was to investigate the impact of preoperative cachexia on postoperative length of stay (LOS) in elderly patients with gastrointestinal cancer. METHODS: This prospective cohort study enrolled 98 patients (≥60 y of age) with gastric or colorectal cancer who were scheduled to undergo curative surgery and were categorized as either having cachexia or as being in a non-cachexia group. The definition of cachexia was patients with >5% loss of stable body weight over the previous 6 mo, a body mass index (BMI) <20 kg/m2 and ongoing weight loss >2%, or sarcopenia and ongoing weight loss >2%...
October 10, 2018: Nutrition
Tomonori Hirashima, Yoshitaka Tamura, Yuki Han, Shoji Hashimoto, Ayako Tanaka, Takayuki Shiroyama, Naoko Morishita, Hidekazu Suzuki, Norio Okamoto, Shinobu Akada, Makoto Fujishima, Yoshihisa Kadota, Kazuya Sakata, Akiko Nishitani, Satoru Miyazaki, Takayuki Nagai
BACKGROUND: In our previous study, colorectal cancer (CRC) patients with active Mycobacterium tuberculosis (MTB) tolerated concurrent anti-cancer chemotherapy (anti-CCT) and anti-MTB chemotherapy. In this study, we retrospectively confirmed the efficacy and safety of concurrent chemotherapy in a greater number of patients with different types of malignancies. METHODS: We enrolled 30 patients who were treated concurrently with anti-CCT and anti-MTB regimens between January 2006 and February 2016...
October 12, 2018: BMC Cancer
Yingchi Yang, Dong Wang, Lan Jin, Guocong Wu, Zhigang Bai, Jin Wang, Hongwei Yao, Zhongtao Zhang
Purpose: The aim of this study was to investigate the prognostic value of the combination of microsatellite instability (MSI) and BRAF V600E mutation in colorectal cancer (CRC). Materials and methods: We compare the prognosis difference among CRC patients with four subtypes according to MSI and BRAF mutation, ie, microsatellite stable/ BRAF wild type (MSS/ BRAF wt), MSS/ BRAF mutation (MSS/ BRAF mut), MSI/ BRAF wt, and MSI/ BRAF mut, by pooling the previous related reports and public available data sets till December 2017 for the first time...
2018: Cancer Management and Research
Xin Wang, Leonid Zamdborg, Hong Ye, Inga S Grills, Di Yan
BACKGROUND: The use of stereotactic body radiotherapy (SBRT) for early-stage primary non-small cell lung cancer (NSCLC) reported excellent local control rates. But the optimal SBRT dose for oligometastatic lung tumors (OLTs) from colorectal cancer (CRC) has not yet been determined. This study aimed to evaluate whether SBRT to a dose of 48-60 Gy in 4-5 fractions could result in similar local outcomes for OLTs from CRC as compared to early-stage NSCLC, and to examine potential dose-response relationships for OLTs from CRC...
October 10, 2018: BMC Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"